Personalizing the Path in mCRPC: Optimizing Chemotherapy and Aggressive Variant Prostate Cancer (AVPC) - Episode 7
Biomarkers, Disease Tracking, and Tumor Evolution
A panel of experts discuss emerging data and future directions in AVPC/NEPC and mCRPC, including novel biomarkers for monitoring disease progression and treatment response (ctDNA, CTCs, CEA, LDH, chromogranin, imaging frequency) when PSA is unreliable, and promising therapeutic strategies such as MYC inhibitors, bispecific antibodies, antibody-drug conjugates, and radioligand therapies.
The panel explores evolving strategies for monitoring AVPC/NEPC and mCRPC when PSA is unreliable. Alternative biomarkers—including ctDNA, circulating tumor cells, CEA, LDH, chromogranin, and more frequent or functional imaging—are discussed for assessing disease burden and treatment response. Looking ahead, experts highlight promising therapeutic directions such as MYC-targeted agents, bispecific antibodies, antibody–drug conjugates, and next-generation radioligand therapies, emphasizing the need for biomarker-driven approaches to improve outcomes in these aggressive disease subsets.